Featured Publications
Our passion at MitRx Therapeutics is to create a better and safer future in the pharmaceutical industry. Our team is dedicated to utilizing the latest machine-learning based approaches to improve the drug discovery process. We acknowledge and respect the complex nature of drug development and are committed to developing innovative solutions that ensure only the safest and most effective candidates reach the market
01
Machine Learning-based Design of MEK1 Inhibitors
Beck TC et al. Application of Pharmacokinetic Prediction Platforms in the Design of Optimized Anti-Cancer Drugs. Molecules. 2022 Jun 8;27(12):3678. doi: 10.3390/molecules27123678. PMID: 35744803; PMCID: PMC9227314.
02
AI-based Pharmacokinetic Predictions in Drug Discovery
Beck TC, Beck KR, Morningstar J, Benjamin MM, Norris RA. Descriptors of Cytochrome Inhibitors and Useful Machine Learning Based Methods for the Design of Safer Drugs. Pharmaceuticals (Basel). 2021 May 17;14(5):472. doi: 10.3390/ph14050472. PMID: 34067565; PMCID: PMC8156202.
03
MEK1 Inhibitor Cardiotoxicity
Beck TC, Arhontoulis DC, Morningstar JE et al. Cellular and Molecular Mechanisms of MEK1 Inhibitor-Induced Cardiotoxicity. JACC CardioOncol. 2022 Nov 15;4(4):535-548. doi: 10.1016/j.jaccao.2022.07.009. PMID: 36444237; PMCID: PMC9700254.
04
Design of Optimized Kappa Opioid Agonists
Beck TC, Reichel CM, Helke KL, Bhadsavle SS, Dix TA. Non-addictive orally-active kappa opioid agonists for the treatment of peripheral pain in rats. Eur J Pharmacol. 2019 Aug 5;856:172396. doi: 10.1016/j.ejphar.2019.05.025. Epub 2019 May 16. PMID: 31103632; PMCID: PMC6696947.
